152 related articles for article (PubMed ID: 20042226)
1. Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?
Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
Gynecol Oncol; 2010 Mar; 116(3):395-8. PubMed ID: 20042226
[TBL] [Abstract][Full Text] [Related]
2. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
Risum S; Loft A; Høgdall C; Berthelsen AK; Høgdall E; Lundvall L; Nedergaard L; Engelholm SA
Acta Oncol; 2011 Apr; 50(3):415-9. PubMed ID: 20698810
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
[TBL] [Abstract][Full Text] [Related]
4. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study.
Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
Gynecol Oncol; 2008 Feb; 108(2):265-70. PubMed ID: 18055006
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of PET/CT for primary ovarian cancer--a prospective study.
Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
Gynecol Oncol; 2007 Apr; 105(1):145-9. PubMed ID: 17229460
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
[TBL] [Abstract][Full Text] [Related]
7. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
8. Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer.
Fruscio R; Sina F; Dolci C; Signorelli M; Crivellaro C; Dell'Anna T; Cuzzocrea M; Guerra L; Milani R; Messa C
Gynecol Oncol; 2013 Dec; 131(3):689-93. PubMed ID: 24076062
[TBL] [Abstract][Full Text] [Related]
9. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
[TBL] [Abstract][Full Text] [Related]
11. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer.
Dauwen H; Van Calster B; Deroose CM; Op de Beeck K; Amant F; Neven P; Berteloot P; Leunen K; Timmerman D; Vergote I
Gynecol Oncol; 2013 Dec; 131(3):694-700. PubMed ID: 23988417
[TBL] [Abstract][Full Text] [Related]
12. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
13. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.
Hynninen J; Kemppainen J; Lavonius M; Virtanen J; Matomäki J; Oksa S; Carpén O; Grénman S; Seppänen M; Auranen A
Gynecol Oncol; 2013 Nov; 131(2):389-94. PubMed ID: 23994535
[TBL] [Abstract][Full Text] [Related]
14. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
16. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
17. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence.
Soussan M; Wartski M; Cherel P; Fourme E; Goupil A; Le Stanc E; Callet N; Alexandre J; Pecking AP; Alberini JL
Gynecol Oncol; 2008 Jan; 108(1):160-5. PubMed ID: 17961640
[TBL] [Abstract][Full Text] [Related]
18. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
19. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]